The N=1 Collaborative is changing the way we view drug development. Their specialty is creating customized therapies tailored to individual patients, paving the way for a unique approach that can leave long-lasting impacts on those with ultra-rare diseases.
Join us as Executive Director Hugh Hempel discusses the origins of N=1, the collaborative effort it takes to advance customized therapies down the pipeline, and what the future holds for the field of individualized medicine.
Show Notes
Rare Disease Research for Drug Development